BARR EVALUATING ACTAVIS GROUP'S COMPETING BID FOR PLIVA D.D.

Barr Pharmaceuticals, Inc. said that is was evaluating the competing bid announced by Actavis Group to purchase PLIVA d.d., based in Zagreb, Croatia for $2.5 billion, or HRK 795. The Company said that it will respond appropriately in a timely manner, but no later than September 8, 2006. Drug Newswire (http://www.drugnewswire.com/5391/)